Management of hypercholesterolemia in children

Pediatric Drugs

Volumn 16, Issue 2, 2014, Pages 105-114

  Braamskamp, Marjet J A M ^a   Hutten, Barbara A ^a   Wiegman, Albert ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NICOTINIC ACID;

APHERESIS; ARTICLE; ATHEROSCLEROSIS; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE DISORDER; AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERLIPEMIA; HUMAN; HYPERCHOLESTEROLEMIA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SCREENING; SEXUAL MATURATION; SITOSTEROLEMIA; SMOKING;

AGE FACTORS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BILE ACIDS AND SALTS; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIFE STYLE; MASS SCREENING; RISK FACTORS;

EID: 84898471047     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0060-2     Document Type: Article

References (61)

1. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA. 1971;17(216):1185-7.
2. Berenson G, Srinivasan S. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338:1650-6.
3. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264:3018-24.
4. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004;31(363):369-70.
5. De Jongh S, Lilien MR, op't Roodt J, Stroes ESG, Bakker HD, Kastelein JJP. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117-21.
6. Goldstein JL, Hobbs HH, Brown MS. Part 12: Lipids chapter 120: familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 2863-913.
7. Innerarity TL, Weisgraber KH, Arnold KAYS, Mahley RW, Kraussf RM, Vega GL, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA. 1987;84:6919-23.
8. Abifadel M, Rabès J-P, Devillers M, Munnich A, Erlich D, Junien C, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520-9.
9. Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit Rev Clin Lab Sci. 2011;48:1-18.
10. Goldstein JL, Schrott HG, Bierman EL. Hyperlipidemia in coronary heart disease and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-68.
11. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;1(49):476-88.
12. Macchiaiolo M, Gagliardi MG, Toscano A, Guccione P, Bartuli A. Homozygous familial hypercholesterolaemia. Lancet. 2012;379:1330.
13. Veerkamp MJ. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol. 2002;1(22):274-82.
14. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol. 2003;92:27-33.
15. Gaddi A, Cicero a FG, Odoo FO, Poli AA, Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3:877-86.
16. De Graaf J, Stalenhoef AF. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr Opin Lipidol. 1998;9:189-96.
17. Li S, Chen W, Srinivasan SR, Xu J, Berenson GS. Relation of childhood obesity/cardiometabolic phenotypes to adult cardiometabolic profile: the Bogalusa Heart Study. Am J Epidemiol. 2012;1(176 Suppl):S142-9.
18. Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2003;1(23):1963-70.
19. Lütjohann D, von Bergmann K. Phytosterolaemia: diagnosis, characterization and therapeutical approaches. Ann Med. 1997;29:181-4.
20. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;3(350):2362-74.
21. Kusters DM, de Beaufort C, Widhalm K, Guardamagna O, Bratina N, Ose L, et al. Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child. 2012;97:272-6.
22. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl. 2011;12:221-63.
23. Griffin TC, Christoffel KK, Binns HJ, McGuire PA. Family history evaluation as a predictive screen for childhood hypercholesterolemia, Pediatric Practice Research Group. Pediatrics. 1989;84:365-73.
24. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands. Lancet. 2001;357:165-8.
25. Huijgen R, Kindt I, Verhoeven SBJ, Sijbrands EJG, Vissers MN, Kastelein JJP, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One. 2010;5:e9220.
26. Avis HJ, Kusters DM, Vissers MN, Huijgen R, Janssen TH, Wiegman A, et al. Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program. J Pediatr. 2012;161:99-103.
27. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl):S213-56.
28. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007;120:e189-214.
29. Schroeder AR, Redberg RF. Cholesterol screening and management in children and young adults should start early - no! Clin Cardiol. 2012;35:665-8.
30. Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA. 2012;307:259-60.
31. Psaty BM, Rivara FP. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA. 2012;18(307):257-8.
32. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ. 2007;22(335):599.
33. Friedman LA, Morrison J a, Daniels SR, McCarthy WF, Sprecher DL. Sensitivity and specificity of pediatric lipid determinations for adult lipid status: findings from the Princeton Lipid Research Clinics Prevalence Program Follow-up Study. Pediatrics. 2006;118:165-72.
34. Obarzanek E, Kimm SYS, Barton BA, Van Horn L, Kwiterovich Jr PO, Simons-Morton DG, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256-64.
35. Niinikoski H, Lagström H, Jokinen E, Siltala M, Rönnemaa T, Viikari J, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;28(116):1032-40.
36. Pahkala K, Heinonen OJ, Simell O, Viikari JS, Rönnemaa T, Niinikoski H, et al. Association of physical activity with vascular endothelial function and intima-media thickness. Circulation. 2011;124:1956-63.
37. Pahkala K, Heinonen OJ, Lagström H, Hakala P, Hakanen M, Hernelahti M, et al. Clustered metabolic risk and leisure-time physical activity in adolescents: effect of dose? Br J Sports Med. 2012;46:131-7.
38. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis. 2009;205:23-32.
39. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;8(366):1267-78.
40. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
41. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJP, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27:1803-10.
42. Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs. 2012;16(72):773-88.
43. Kusters DM, Lahsinoui HH, van de Post JAM, Wiegman A, Wijburg FA, Kastelein JJP, et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2012;10:363-78.
44. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg a SP, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116:664-8.
45. West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet. 1980;25(2):873-5.
46. Perry CM. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. Paediatr Drugs. 2010;1(12):133-40.
47. Stein EA, Marais AD, Szamosi T, Raal FJ, Schurr D, Urbina EM, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156:231-6.e1-3.
48. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;15(90):1092-7.
49. Knopp R. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729-41.
50. Clauss S, Wai K-M, Kavey R-EW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154:869-72.
51. Van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;21(52):1421-9.
52. Pijlman AH, Huijgen R, Verhagen SN, Imholz BPM, Liem AH, Kastelein JJP, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209:189-94.
53. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
54. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-900.
55. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
56. McGowan MP, Tardif J-C, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.
57. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40-6.
58. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247-55.
59. Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl. 2013;14:19-27.
60. Palcoux J-B, Atassi-Dumont M, Lefevre P, Hequet O, Schlienger J-L, Brignon P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial. 2008;12:195-201.
61. Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2012;6:331-9.